65 results
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
HIV-AIDS Preventing Clinical ... disease and tested positive ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Toxoplasma IgG positive ... IDSA #Prevention #Treatment ... #opportunistic ... #infections #HIVAIDS ... #management #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
CNS Infection in HIV / AIDS - Differential Diagnosis Framework

Principles of HIV-Associated CNS Opportunistic Infections:
 •
should be based on clinical ... Antimicrobial treatment ... status, and focal neurologic ... Demyelinating disease caused ... and <25% culture positive
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
• In rare cases ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
for effective treatment ... IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
IDSA #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Diagnosis and Management ... 40, F:M 9:1 • Clinical ... - Anti-dsDNA - Positive ... in 60-80% of cases ... life-threatening • Treatment
Pneumocystis jirovecii Pneumonia 
Clinical 
 • Caused by Pneumocystis jirovecii (formerly carinil) 
 • Immunocompromised host
jirovecii Pneumonia Clinical ... • Caused by ... • Seen in HIV positive ... often elevated Treatment ... Pneumonia #Diagnosis #Management
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS ... #pharmacology